Form 4: CVS Health Director Anne Finucane Acquires Stock Units

CVS Health director Anne Finucane acquired 1,544.0041 deferred stock units as part of the company's non-employee director compensation policy.

Summary

• Director Anne Finucane acquired 1,544.0041 deferred stock units on May 14, 2026.
• The units were issued in lieu of a semi-annual cash retainer for board service.
• The transaction was valued at $97.15 per unit based on the market price.
• Following this transaction, the director holds a total of 18,355.0364 deferred stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Demonstrates alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Value of deferred stock units is subject to market fluctuations in CVS Health common stock.

Future Outlook

The deferred stock units will be converted into common stock at a future date as elected by the reporting person.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common among large-cap companies to ensure board members maintain a long-term equity stake in the firm.

Comparison to Industry Standards

• The use of deferred stock units for director retainers is a standard corporate governance practice among S&P 500 companies to align director incentives with long-term shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation practices.

Next Steps

• Conversion of deferred stock units into common stock at a future date determined by the director.

Key Dates

Keywords

CVS Health, Insider Trading, Form 4, Director Compensation, Equity Incentive Plan